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undergoes significant first pass metabolism.1 4 At low to moderate doses, blood ethanol concentrations after oral dosing are significantly lower than those seen after intravenous administration. A reduction of this first pass metabolism has been associated with fasting, chronic alcoholism,2 female sex,1 and with cimetidine,3 and aspirin5 ingestion. It has been suggested that resultant increase in blood ethanol concentrations could lead to enhanced longterm toxicity, and have important social and forensic implications in relation to the degree of impairment in motor function. It has been suggested that at least part of this first pass metabolism takes place in the stomach mediated by several enzymes of the alcohol dehydrogenase isoenzyme family,24 known to be present in the gastric mucosa. 6 The histamine receptor antagonist ranitidine, has been shown to inhibit gastric alcohol dehydrogenase isoenzyme in humans,7 but studies in healthy volunteers of the effect of ranitidine ingestion on the bioavailability of ethanol are conflicting. As a high prevalence of problem drinking is encountered in patients with gastrointestinal disease, in particular peptic disorders,29 increased bioavailability of ethanol during ranitidine treatment is of potential clinical importance. We sought to determine the effect of ranitidine on the bioavailability of ethanol in a population referred for assessment of gastrointestinal symptoms who were therefore potential recipients of ranitidine as treatment. This also enabled an investigation of the potential effects of differences in gastric histology on ethanol bioavailability.
Methods

Subjects
Consecutive adult subjects due to undergo routine, outpatient, upper gastrointestinal endoscopy were recruited to the study. Subjects with an alcohol intake of greater than 40 g/day, previous gastric surgery, those receiving H2 receptor antagonists other than ranitidine, and those with major concomitant medical problems were excluded. No patient was receiving concomitant treatment at the time of the studies. Table I shows subject characteristics, indications for endoscopy, and endoscopic and histological findings.
Twenty nine subjects (15 male, 14 female) gave informed consent for the study, which was approved by the joint ethics committee of the University of Newcastle upon Tyne and Newcastle Health Authority. All patients were white. Thirteen subjects (six males, seven females) had been prescribed ranitidine 150 mg twice daily for at least three weeks (median six weeks, range 3-48) before . Six subjects in the ranitidine group had a further oral ethanol pharmacokinetic study performed two weeks after ranitidine had been withdrawn.
First pass metabolism
The first pass metabolism of ethanol was determined in each patient by measuring the difference in area under the curve (AUC) of the blood ethanol/time curves. The AUCs were calculated using the trapezoidal method of integration. First pass metabolism was calculated and expressed as the difference between the AUC(intravenous) and AUC(oral). 10 .0 mg/100 ml and 16&5 v 7.5 mg/100 ml/h respectively) than in the control group (Fig 1,  Table II ). In contrast there were no significant differences between the groups in the median peak blood ethanol concentration and AUC after intravenous ethanol (Table III) . The first pass metabolism of this dose of ethanol (as calculated by the difference between AUC(intravenous) and AUC(oral)) was therefore significantly lower in the ranitidine treated group (estimated median difference between groups 5.0 mg/100 ml/h (Fig  2, Table IV ).
In addition, peak blood ethanol concentrations and AUC(oral) were significantly reduced in all subjects (n=6) when restudied after the withdrawal of ranitidine (Fig 3, 14 showed peak blood ethanol concentrations after oral intake that were higher after treatment with either cimetidine or ranitidine, although in only seven were the differences statistically significant. 11-3 19202223 Levitt suggests that, rather than an effect on gastric alcohol dehydrogenase isoenzyme activity, the results are caused by the effect of the H2 receptor antagonists on either ethanol absorption or hepatic ethanol metabolism. The lack of significant effect of ranitidine on the pharmacokinetics of intravenous ethanol seen in this study, however, shows that hepatic metabolism is unlikely to be affected by the drug, and cannot therefore satisfactorily explain the observed difference in the oral studies. It has also been shown previously that ranitidine has no affect on hepatic blood flow.34 Similarly, it is unlikely that ranitidine enhances the absorption of ethanol by increasing the rate of gastric emptying as ranitidine has been shown in at least one study to delay gastric emptying in both healthy volunteers and subjects with duodenal ulceration.35
Likewise, it is doubtful that the increase in gastric pH resulting from ranitidine has any effect on the absorption of ethanol as the H2 receptor antagonist famotidine and the proton pump inhibitor omeprazole have not been shown to have any effect on the bioavailability of ethanol9 (although studies strictly comparable to our own have not been carried out). The second finding also argues against the effect of ranitidine on gastric alcohol dehydrogenase isoenzyme activity caused by a nonspecific pH effect. Further confirmation of the effect of ranitidine on the bioavailability of ethanol is provided by the reduction in peak blood ethanol concentration and AUC(oral) in all subjects withdrawn from treatment. These subjects did not have acid related lesions on endoscopy and therefore the observed decrease in bioavailability could not result from resolution of gastric mucosal abnormality. Furthermore, there was no consistent relation between gastric histology and bioavailability of ethanol in this study irrespective of ranitidine ingestion.
Previous studies examining the bioavailability of ethanol and ranitidine have used young healthy male volunteers and experimental conditions such as large doses of ethanol in the fasting state, in which the first pass metabolism of alcohol would be reduced. Our study population, however, with gastrointestinal symptoms or disorders are the very subjects likely to be prescribed H2 receptor antagonists and constitute, we therefore believe, a In this study the dose of ethanol was chosen to maximise the first pass metabolism, which may account for as much as 80-90% of the total metabolism seen (Fig 2) . First pass metabolism is of importance at twice the dose used in this study' and is probably so at larger doses consumed more slowly in the usual social setting compared with rapid consumption hitherto used experimentally, particularly in the fasting state. As risk levels for the development of alcoholic liver disease in susceptible subjects have been claimed to be as low as 40 g of ethanol per day in men and less in women,37 longterm reduction of first pass metabolism of low to moderate doses of ethanol associated with prolonged maintenance treatment with ranitidine, one of the most widely prescribed of all drugs, may be clinically significant. Similarly, while the concentrations of blood alcohol attained by patients in this study did not exceed the limits of legal significance, they did in some cases none the less approach them, even in the low doses used, contradicting previous claims that any reduction in first pass metabolism of ethanol brought about by H2 receptor antagonists is of no significance in patients who drive. 
